JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

Search

Certara Inc

Closed

SectorHealthcare

6.17 0.82

Overview

Share price change

24h

Current

Min

6.12

Max

6.3

Key metrics

By Trading Economics

Income

-7.4M

-5.9M

Sales

-968K

104M

P/E

Sector Avg

100.714

67.147

Profit margin

-5.688

Employees

1,515

EBITDA

8.6M

32M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+44.07% upside

Dividends

By Dow Jones

Next Earnings

11 maj 2026

Market Stats

By TradingEconomics

Market Cap

-77M

957M

Previous open

5.35

Previous close

6.17

News Sentiment

By Acuity

50%

50%

186 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Certara Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 kwi 2026, 23:08 UTC

Earnings

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 kwi 2026, 23:07 UTC

Earnings

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 kwi 2026, 22:20 UTC

Earnings

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 kwi 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 kwi 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30 kwi 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 kwi 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 kwi 2026, 23:22 UTC

Earnings

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 kwi 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 kwi 2026, 22:52 UTC

Earnings

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 kwi 2026, 22:33 UTC

Earnings

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 kwi 2026, 22:32 UTC

Earnings

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 kwi 2026, 22:32 UTC

Earnings

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 kwi 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 kwi 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 kwi 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 kwi 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 kwi 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 kwi 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30 kwi 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 kwi 2026, 22:05 UTC

Earnings

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 kwi 2026, 21:57 UTC

Earnings

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 kwi 2026, 21:56 UTC

Earnings

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 kwi 2026, 21:56 UTC

Earnings

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 kwi 2026, 21:55 UTC

Earnings

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 kwi 2026, 21:54 UTC

Earnings

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 kwi 2026, 21:54 UTC

Earnings

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 kwi 2026, 21:53 UTC

Earnings

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 kwi 2026, 21:49 UTC

Earnings

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 kwi 2026, 21:49 UTC

Earnings

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Peer Comparison

Price change

Certara Inc Forecast

Price Target

By TipRanks

44.07% upside

12 Months Forecast

Average 8.5 USD  44.07%

High 10 USD

Low 7 USD

Based on 8 Wall Street analysts offering 12 month price targets forCertara Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

3

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

11.27 / 12.79Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

186 / 347 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat